Potent growth-inhibitory effect of TRAIL therapy mediated by double-regulated oncolytic adenovirus on osteosarcoma.

Molecular and Cellular Biochemistry
Chunbao LiYujie Liu

Abstract

Osteosarcoma (OS) severely threatens the health of young people and understanding on the molecular mechanisms of OS etiology enables gene therapy to become an effective therapeutic modality. However, insufficient expression level of genes using existing vectors limits the clinical application of gene therapy for OS. To solve the problem, we developed an oncolytic adenoviral vector, OAT, which can selectively and efficiently replicate in OS cells to enhance the expression of transferred genes. We demonstrated that OAT-mediated TRAIL expression is significantly elevated after infection of OS cells than replication-incompetent Ad5 vector. Increased antitumor capacity was observed in OS cells after OAT-TRAIL treatment both in vitro and in vivo. In normal cells, adenoviral replication, TRAIL expression and growth-inhibiting effect were quite limited when OAT-TRAIL was administrated, showing a high biosafety of this oncolytic adenoviral vector. Collectively, we generated an efficient and promising expression vector for OS gene therapy.

References

Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J W Shay, S Bacchetti
Oct 20, 2000·The Journal of General Virology·R AlemanyD T Curiel
Feb 25, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Akseli HemminkiDavid T Curiel
Nov 25, 2003·Pediatric Research·Elena Sotillo-PiñeiroAna Patiñno-García
Jan 22, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adhiambo M WitloxWinald R Gerritsen
Jun 23, 2004·Biochemical and Biophysical Research Communications·Min KimKenneth Cowan
Jun 15, 2007·Cancer Biology & Therapy·Yuichiro OshimaTakashi Tokino
Nov 28, 2007·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Mitsunori KayaToshihiko Yamashita
Apr 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jingjing LuoCheng Qian
Aug 30, 2008·Paediatric Drugs·Alexander J ChouRichard Gorlick
Apr 21, 2009·Expert Review of Anticancer Therapy·Kathleen O'Day, Richard Gorlick
May 5, 2009·Cancer Biotherapy & Radiopharmaceuticals·You-shui GaoXuan-song Cai
Apr 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gaëlle PicardaFrançoise Rédini
May 27, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Petri NokisalmiAkseli Hemminki
Jun 25, 2010·Cancer Biology & Therapy·Lian Li XiaoXin Yuan Liu
Jul 29, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Anniina KoskiAkseli Hemminki
Sep 3, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Juan J RojasRamon Alemany
Jan 5, 2011·Journal of Cancer Research and Clinical Oncology·Guidong LiNaoto Endo
Feb 24, 2011·International Journal of Cancer. Journal International Du Cancer·Emmanuelle DavidFrédéric Blanchard
Mar 26, 2011·Molecular and Cellular Biochemistry·Youguang ZhaoMingli Li

❮ Previous
Next ❯

Citations

Feb 13, 2015·Future Oncology·Romain GuihoFrançoise Redini
Apr 29, 2014·Molecular and Cellular Biochemistry·Ruhui LiShaokun Zhang
Feb 11, 2015·Molecular and Cellular Biochemistry·Xiaohui SunYing Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.